Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) PT at $9.73

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) have been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $9.73.

Several equities analysts recently commented on ALLO shares. William Blair reaffirmed an “outperform” rating on shares of Allogene Therapeutics in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Allogene Therapeutics in a research note on Friday, November 8th. Finally, Piper Sandler dropped their price target on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th.

Allogene Therapeutics Stock Down 1.5 %

NASDAQ ALLO opened at $1.92 on Friday. Allogene Therapeutics has a fifty-two week low of $1.78 and a fifty-two week high of $5.78. The stock has a market cap of $402.57 million, a price-to-earnings ratio of -1.23 and a beta of 0.86. The business has a fifty day moving average of $2.30 and a 200-day moving average of $2.53.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ALLO. Primecap Management Co. CA boosted its position in shares of Allogene Therapeutics by 4.1% during the 2nd quarter. Primecap Management Co. CA now owns 5,670,226 shares of the company’s stock valued at $13,212,000 after acquiring an additional 221,840 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Allogene Therapeutics by 14.4% in the third quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock valued at $9,037,000 after buying an additional 407,070 shares during the period. Perceptive Advisors LLC acquired a new stake in shares of Allogene Therapeutics during the second quarter worth $6,349,000. Dimensional Fund Advisors LP increased its stake in shares of Allogene Therapeutics by 24.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock valued at $5,944,000 after acquiring an additional 507,021 shares during the last quarter. Finally, Lynx1 Capital Management LP acquired a new stake in Allogene Therapeutics in the second quarter worth $5,192,000. 83.63% of the stock is currently owned by institutional investors and hedge funds.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).